Celyad Oncology is pleased to announce Georges Rawadi as its new CEO, effective as of March 23, with starting date April 17. Michel Lussier will continue to serve as Interim CEO until April 17 to facilitate transition. Georges Rawadi has over 20 years of experience in pharma/biotech, as research director, business developer, CEO and board member. He spent four years at Celyad Oncology from 2014-2018 as Vice-President Business Development & Intellectual Property, and has insightful knowledge of both the company and the CAR-T space.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CYAD:
- Celyad Oncology appoints Georges Rawadi as its new CEO
- Celyad Oncology reports full year 2022 financial results and recent business highlights
- Celyad Oncology to announce full year 2022 financial results and host conference call
- Celyad to recognize non-cash impairment of EUR 35.1M for FY22
- Celyad Oncology announces non-cash impairment